(VIANEWS) – Trading volume surged to 228.3 million shares, up from a full-day average of around 125,600 shares in the preceding 30 days, making the firm the greatest gainer and most often traded on major U.S. exchanges.

Fibromyalgia is a kind of chronic pain that affects 5 million to 15 million people, or 2% to 6% of the US population, and is most frequent in adults aged 30 to 50.

Under the Breakthrough Designation program, the FDA will give the company with priority review and direct conversation on device development through commercialization.

Furthermore, there are government programs that may help with Medicare reimbursement. The stock is currently up 251.9 percent year to date, while the SPDR Health Care Select Sector ETF is up 13.5 percent and the S&P 500 is up 15.3 percent.

Shares of NeuroMetrix (NURO) jumped by a staggering 207.98% to $10.04 at 05:43 EST on Wednesday, following the last session’s downward trend. NASDAQ Composite (NURO) is rising 1.57% to $14,498.88, following the last session’s upward trend. This seems, so far, an all-around bullish trend exchanging session today.

NeuroMetrix’s last close was $2.92, 49.48% under its 52-week high of $5.78.

Volume

Today’s last reported volume for NeuroMetrix is 282027833 which is 244217.44% above its average volume of 115435.

NeuroMetrix’s Revenue

Year-on-year quarterly revenue growth declined by 0.8%, now sitting on 7.36M for the twelve trailing months.

NeuroMetrix’s Stock Yearly Top and Bottom Value

NeuroMetrix’s stock is valued at $10.04 at 05:44 EST, way above its 52-week high of $5.78.

NeuroMetrix’s Moving Average

NeuroMetrix’s value is way higher than its 50-day moving average of $3.38 and way above its 200-day moving average of $3.48.

Previous days news about NeuroMetrix (NURO)

Neurometrix stock more than triples on massive volume after fibromyalgia treatment gets FDA boost. According to MarketWatch on Tuesday, 20 July, “Shares of NeuroMetrix Inc. rocketed 241% toward a two-year high on record volume, after the Massachusetts-based medical device company said its Quell transcutaneous electric nerve stimulator received “Breakthrough Designation” from the Food and Drug Administration to treat fibromyalgia symptoms in adults. ”

More news about NeuroMetrix (NURO).

LEAVE A REPLY

Please enter your comment!
Please enter your name here